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Measuring changes in substrate 
utilization in the myocardium 
in response to fasting using 
hyperpolarized [1-13C]butyrate and 
[1-13C]pyruvate
Jessica A. M. Bastiaansen1,2, Matthew E. Merritt3 & Arnaud Comment4
Cardiac dysfunction is often associated with a shift in substrate preference for ATP production. 
Hyperpolarized (HP) 13C magnetic resonance spectroscopy (MRS) has the unique ability to detect real-
time metabolic changes in vivo due to its high sensitivity and specificity. Here a protocol using HP [1-13C]
pyruvate and [1-13C]butyrate is used to measure carbohydrate versus fatty acid metabolism in vivo. 
Metabolic changes in fed and fasted Sprague Dawley rats (n = 36) were studied at 9.4 T after tail vein 
injections. Pyruvate and butyrate competed for acetyl-CoA production, as evidenced by significant 
changes in [13C]bicarbonate (−48%), [1-13C]acetylcarnitine (+113%), and [5-13C]glutamate (−63%), 
following fasting. Butyrate uptake was unaffected by fasting, as indicated by [1-13C]butyrylcarnitine. 
Mitochondrial pseudoketogenesis facilitated the labeling of the ketone bodies [1-13C]acetoacetate 
and [1-13C]β-hydroxybutyryate, without evidence of true ketogenesis. HP [1-13C]acetoacetate was 
increased in fasting (250%) but decreased during pyruvate co-injection (−82%). Combining HP 13C 
technology and co-administration of separate imaging agents enables noninvasive and simultaneous 
monitoring of both fatty acid and carbohydrate oxidation. This protocol illustrates a novel method 
for assessing metabolic flux through different enzymatic pathways simultaneously and enables 
mechanistic studies of the changing myocardial energetics often associated with disease.
An emerging treatment avenue for ischemic heart disease is modulation of the substrate preference of the myo-
cardium to improve the production of ATP1–3. Substrate selection is a clinically important parameter that varies 
with the severity of the myocardial pathology and is subject to manipulation by pharmacological intervention3,4. 
The long history of measuring substrate preference has yielded many conflicting results, but there is a general 
consensus that the onset of heart failure is characterized by a decreased utilization of fatty acids, and an increase 
in carbohydrate metabolism3. Measuring substrate selection in vivo in a rapid and reproducible manner without 
ionizing radiation would constitute a fundamental advance in the diagnosis and treatment of heart failure and 
could help in correctly choosing the most effective intervention in a single patient, i.e., personalized healthcare.
The heart uses a variety of fuel sources to meet its energy requirements, namely fatty acids, ketone bodies, and 
carbohydrates; the consumption of the latter being up-regulated in the failing heart5. Since the complete oxidation 
of a single glucose molecule provides more molecules of ATP per mole of oxygen than any other substrate6, meta-
bolic approaches for increasing cardiac efficiency include suppressing fatty acid oxidation and increasing glucose 
oxidation3. Recently, this hypothesis has been called into question, with the suggestion that insulin resistance in 
the heart has a cardioprotective effect7. With alternative hypotheses for optimizing myocardial function present, 
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new techniques that can measure substrate competition will serve an important purpose in establishing which 
model of myocardial metabolism is most accurate.
Plasma substrate concentrations can vary dramatically depending on the physiological state of the body and as 
a result the myocardium modulates its substrate selection in order to maintain high levels of ATP8. For instance, 
fasting leads to an increase of circulating free fatty acids (FFA)9, an acceleration of lipid oxidation and a reduc-
tion of glycolysis in peripheral tissues10, as well as an elevation of ketone body concentrations, which eventually 
inhibit carbohydrate and fatty acid oxidation11,12. Acetyl-CoA is the metabolite formed at the crossroads between 
lipid and carbohydrate metabolism and it is located at the entry of the tricarboxylic acid (TCA) cycle (Fig. 1). 
It is produced from fatty acids via β -oxidation and from carbohydrates through the glycolytic pathway, via the 
intramitochondrial pyruvate dehydrogenase (PDH) complex. Substrate selection is regulated by many mecha-
nisms, including the intramitochondrial acetyl-CoA to CoA ratio. An increased ratio results in the inhibition of 
PDH activity whereas a decreased ratio activates PDH13. When acetyl groups are abundant they can be stored as 
acetylcarnitine, a reaction catalyzed by carnitine acetyl transferase (CAT)8.
Recent developments in hyperpolarized 13C magnetic resonance (MR) allow the study of real-time metabo-
lism of 13C labeled pyruvate, providing a direct measurement of the flux through PDH by the formation of CO2 
and bicarbonate14–16. Hyperpolarized 13C pyruvate alone, has been used in promising pre-clinical investigations 
of myocardial metabolism of the failing heart17–20. The effect of increased fatty acid availability on the metabolism 
of hyperpolarized pyruvate has been studied in perfused rat heart14,21, while hyperpolarized [1-13C]butyrate was 
recently proposed as a substrate to study cardiac fatty acid metabolism22,23. Metabolism of hyperpolarized [1-13C]
butyrate provides an abundance of metabolic information about its exchange with butyrylCoA via the formation 
of [1-13C]butyrylcarnitine, TCA cycle turnover via the formation of [5-13C]citrate, the 13C transfer rate between 
α -ketoglutarate and glutamate through the evolution of the [5-13C]glutamate signal, the enzymatic activity of 
CAT via the formation of [1-13C]acetylcarnitine, and a process referred to as pseudoketogenenesis24,25, via the 
formation of [1-13C]β -hydroxybutyrate (BHB) and [1-13C]acetoacetate (AcAc). Note that TCA cycle flux can be 
probed through the measurement of the [5-13C]citrate signal evolution following the injection of hyperpolarized 
[1-13C]acetate26, but neither [5-13C]citrate nor [5-13C]glutamate would be detectable if hyperpolarized [1-13C]
acetate and [1-13C]pyruvate were co-injected because of the overlapping resonances of [1-13C]pyruvate hydrate 
and [1-13C]acetate, respectively.
The considerable advantage of the hyperpolarized 13C MR method is that substrate selection is monitored by 
the appearance of specific metabolites produced by pathways leading to acetyl-CoA production and its subse-
quent entry into the TCA cycle proper. The aim of this study was to measure the change in substrate utilization, 
in vivo and in real-time, in response to an induced shift in metabolism using the co-administration of hyperpo-
larized [1-13C]pyruvate and [1-13C]butyrate.
Figure 1. Metabolism of [1-13C]pyruvate and [1-13C]butyrate in the myocardium in vivo. Metabolic 
scheme indicating the propagation of the 13C label from pyruvate to its downstream metabolites with red 
arrows and those of butyrate with blue arrows. The 13C label of [1-13C]pyruvate will not enter the TCA cycle. 
After an overnight fast, ketone body uptake will increase the intracellular acetoacetate and β -hydroxybutyrate 
concentrations. Detectable metabolite 13C resonances are indicated with grey boxes. CAT: carnitine 
acetyltransferase; CS: citrate synthase; AAT: acetoacetyl-CoA thiolase; OAT: 3-oxoacid CoA transferase; PT: 
pyruvate transporter; PDH: pyruvate dehydrogenase, LDH: lactate dehydrogenase; ALT: alanine transaminase; 
BHBDH: β -hydroxybutyrate dehydrogenase; CA: carbonic anhydrase; VX: transport and conversion to 
glutamate.
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Results
Carbohydrate and Fatty Acid Metabolism in the Fed State. Hyperpolarized [1-13C]pyruvate metab-
olism led to the detection of [1-13C]lactate, [1-13C]alanine, 13CO2, 13C bicarbonate and [1-13C]pyruvate hydrate 
(Fig. 2a). The measured metabolite ratios between total lactate, bicarbonate and alanine relative to pyruvate were 
0.049 ± 0.010, 0.027 ± 0.012 and 0.027 ± 0.009 respectively (Fig. 3a–c). The detection of both bicarbonate and 
CO2 in the fed animals allowed us to determine the myocardial pH. A stable value of 7.3 ± 0.1 was observed and 
demonstrated that the injections did not significantly disturb pH during the experiment (Supplemental Fig. S1).
Butyrate metabolism was similarly informative. The C1 of butyrate has a relatively long longitudinal relaxation 
time (T1) compared to longer chain fatty acids and its resonance signal does not overlap with that of [5-13C]gluta-
mate like [1-13C]acetate does (Fig. 2b). The following butyrate-derived metabolites were detected in vivo: [5-13C]
glutamate, [1-13C]β -hydroxybutyrate, [5-13C]citrate, [1-13C]acetoacetate, [1-13C]butyrylcarnitine, and [1-13C]
acetylcarnitine (Table 1). The resonance observed at 176.5 ppm was assigned to that of [1-13C]butyrylcarnitine 
based on high resolution 13C MR of a mixture containing both 13C labeled acetylcarnitine and butyrylcarnitine 
(Supplemental Fig. S2). Butyrate β -oxidation produces two units of acetyl-CoA, only one of which is labeled and 
hyperpolarized. As a fraction of the parent butyrate signal, acetylcarnitine (Fig. 4a) was approximately twice the 
intensity of the glutamate (Fig. 4b) peaks and four times the intensity of the butyrylcarnitine (Fig. 4c) and aceto-
acetate peaks (Fig. 4d) and showed nearly identical intensities between the fed and fasted state. The normalized 
fractions of acetylcarnitine, glutamate, butyrylcarnitine, and acetoacetate relative to butyrate were 0.008 ± 0.001, 
0.004 ± 0.001, 0.0012 ± 0.0004, and 0.0012 ± 0.0002 respectively in the fed state (Fig. 4).
Figure 2. In vivo myocardial 13C spectra acquired during hyperpolarized MR experiments. (a) In vivo 
cardiac 13C spectrum recorded after the injection and metabolism of hyperpolarized [1-13C]pyruvate in a fed 
animal. (b) In vivo cardiac 13C spectra recorded after the injection and metabolism of hyperpolarized [1-13C]
butyrate in the fed and fasted state, without the presence of pyruvate. (c) Spectral time course of myocardial 
metabolism in vivo following the co-injection of hyperpolarized [1-13C]butyrate and [1-13C]pyruvate. (d) A sum 
spectrum with expansion to show the downstream metabolites of HP butyrate and pyruvate in the case of co-
injection.
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Figure 3. Ratios of measured metabolite signals following hyperpolarized pyruvate metabolism. Signal 
ratios of lactate (a) bicarbonate (b) and alanine (c) relative to pyruvate where hyperpolarized [1-13C]pyruvate 
was either injected separately or co-injected with hyperpolarized [1-13C]butyrate, in both fed and fasted 
animals. *P = 0.02 in co-injection compared with single injection groups, §P = 0.03 in fasted groups compared 
with fed groups, ***P = 0.001 in fasted groups vs. fed groups.














Table 1.  Chemical shifts of observed metabolites following the injection of hyperpolarized sodium [1-13C]
butyrate and sodium [1-13C]pyruvate.
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Substrate competition was clearly evident upon co-injection of the agents. Hyperpolarized 13C MRS clearly 
show the time evolution of both hyperpolarized substrates (Fig. 2c). Although there was some spectral overlap, 
most metabolites could be detected in the co-injection experiments (Fig. 2d). The competition presented by 
butyrate results in a decrease in the bicarbonate signal, and a significant increase in the lactate to pyruvate ratio. 
From the perspective of butyrate metabolism, the co-injection of pyruvate produced multiple signs of competi-
tion in the fed state. The acetylcarnitine to butyrate ratio (Fig. 4b), increased upon co-injection, but did not reach 
statistical significance. The [5-13C]glutamate to butyrate ratio (Fig. 4b) decreased significantly upon introduction 
of pyruvate (0.41 ± 0.06 to 0.08 ± 0.01). Additionally, the co-injection of pyruvate nearly quenched the appear-
ance of acetoacetate derived from butyrate,(0.0012 ± 0.0002 to 0.0002 ± 0.0002) (Fig. 4d).
The fractional contribution of the downstream metabolites to the total detected signal was not significantly 
different when fasting or in the case of co-injection (Supplemental Fig. S3).
Carbohydrate and Fatty Acid Metabolism in the Fasted State. Fasting led to significant changes in 
both the pyruvate and butyrate control experiments and in the substrate selection protocol. Alanine as a fraction 
of pyruvate signal was largely constant across all injection conditions (Fig. 3c). After an overnight fast, the ratio 
of bicarbonate to pyruvate reduced significantly in both the single and co-injection groups, and a significant 
increase in the lactate to pyruvate ratios could be observed (Fig. 3a).
In the butyrate control, a significant increase of the ketone body acetoacetate was observed in both the single 
and co-injection experiment after fasting (Fig. 4d). The ratio of butyrylcarnitine to butyrate was stable in the fed 
relative to the fasted cases (Fig. 4c).
Co-injection of pyruvate and butyrate in the fasted state resulted in changes to the downstream metabolites 
of both metabolic probes compared to the fed animals. The lactate signal rose significantly between the fed and 
fasted states during co-injection, while the alanine and bicarbonate signals did not show significant changes. 
From the perspective of butyrate metabolism in the fasted state, the co-injection of pyruvate decreased the glu-
tamate to butyrate ratio (Fig. 4b) and also that of acetoacetate (Fig. 4d). Fasting did not induce a change in the 
acetylcarnitine to butyrate ratio when comparing the butyrate protocol to the competition protocol (Fig. 4a). 
Additionally, fasting results in an apparent restoration of the acetoacetate signal even in the presence of pyruvate 
compared with fed animals (Fig. 4d).
Discussion
During the switch to a fasting profile, ketone concentrations climb in the plasma, as does the availability of fatty 
acids. Therefore, in addition to a change in enzyme expression in the myocardium, there is a different profile of 
Figure 4. Ratios of measured metabolite signals following hyperpolarized butyrate metabolism. In vivo 
metabolite ratios of 13C labeled acetylcarnitine (a), glutamate (b), butyrylcarnitine (c), and acetoacetate (d) 
relative to their hyperpolarized metabolic precursor butyrate. Animals were exposed to a single injection of 
butyrate, or a co-injection of butyrate and pyruvate. *P = 0.01 in co-injection compared with single injection 
groups, **P = 0.006 in co-injection compared with single injection groups, §P = 0.05 in fasted groups compared 
with fed groups, ‡P = 0.09 in fasted groups vs. fed groups. Butyrylcarnitine cannot be directly observed during 
co-injection due to spectral overlap.
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circulating substrates available to the heart. The circulating glucose concentration in the fed animals was meas-
ured as 9.0 ± 0.7 mM and in the fasted animals it was 4.5 ± 1.0 mM. These changes in substrate availability will 
affect the signals derived from the hyperpolarized experiments.
Pyruvate metabolism largely recapitulated previous studies and is summarized in supplemental information. 
Like pyruvate, butyrate metabolism is exquisitely sensitive to the nutritional state of the animal. The 13C labe-
ling of butyrylcarnitine was stable in both the fed and fasted cases (Fig. 4c), indicating that butyrate transport, 
reflected by 13C labeling of butyrylcarnitine, in the myocardium was not affected by fasting. The acetoacetate 
resonances were more intense in fasted animals, a direct result of increased ketone body concentrations10 and 
the pseudoketogenic effect27. The 13C labeling observed in β -hydroxybutyrate and acetoacetate is a result of the 
exchange between acetoacetyl-CoA and free, unlabeled acetoacetate in the mitochondria, as opposed to true 
synthesis from two acetyl-CoA precursor units. These ketone bodies were also detected in a perfused heart model 
injected with hyperpolarized [1-13C]butyrate22, leading us to believe that they are not an artifact of circulation 
from the liver. True ketogenesis would result in the 13C labeling of [3-13C]acetoacetate (Fig. 1), a resonance 
(~209 ppm) which was never observed. In previous studies using hyperpolarized acetate, which is not β -oxidized, 
ketone body labeling in the muscle was entirely absent26,28–32, supporting our hypothesis of negligible 13C label 
flux from acetyl-CoA to the ketone bodies in the heart. Acetoacetyl-CoA formation is therefore necessary for 
observation of β -hydroxybutyrate (Fig. 5a).
Interpretation of the glutamate signal intensities in carbon-13 NMR is subject to a long history of research 
on the glutamate-oxaloacetate transaminase (GOT) and its interplay with the malate-aspartate shuttle (MAS). 
Glutamate is 13C labeled by exchange with α -ketoglutarate, a pathway alternatively referred to as VX33 or F134. 
The glutamate to acetylcarnitine ratio was lower in the fasted compared to fed state while the acetylcarnitine 
to butyrate ratio remained unchanged, indicating a decrease in glutamate labeling (Fig. 5a). Based on com-
parisons relative to the butyrate signal, acetylcarnitine was not significantly changed by fasting (Fig. 4a) and 
the fluxes maintaining the acetylcarnitine pool acting as storage for excess mitochondrial acetyl-CoA do not 
seem to be affected on the time scale of the experiment35. The glutamate pool size remains unchanged for up 
to a 48 h fast8. Therefore it is likely that the decrease in glutamate signal is not a result of a change in glutamate 
pool size. Substrate competition from circulating, unlabeled nutrients or a change in the equilibration between 
α -ketoglutarate and glutamate could both be mechanisms underlying the decreased glutamate signal.
Figure 5. Diagrams of the metabolic pathways probed by the HP experiments. (a) Diagram of butyrate 
metabolism in the fed and fasted case. Fasting lowers the apparent glutamate signal while raising the 
acetoacetate signal. As carbohydrates and ketones are not labeled, they are grayed out. (b) The impact of 
substrate competition in the fed state. The extra source of acetyl units drives the acetylcarnitine pool size up, 
while the simultaneous presence of butyrate and pyruvate drives down the appearance of [5-13C]glutamate and 
[13C]bicarbonate. It is hypothesized that the decreased acetoacetate signal is ascribed to the effects of antiporting 
associated with the mitochondrial pyruvate transporter. (c) Substrate competition in the fasted state mirrors 
that of the fed state, though fasting restores some of the [1-13C]acetoacetate production. Acetylcarnitine is not 
significantly different between panels a and c. (d) A comparison of the fed versus fasted state (Panel b versus 
Panel c). Fasting produces an increase in the acetoacetate signal but a decrease in the acetylcarnitine signal. 
Fasting also results in a lower [13C]bicarbonate signal whenever it is compared to the fed state.
www.nature.com/scientificreports/
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Competition between butyrate and pyruvate in the fed animals, compared with a single injection of butyrate 
or pyruvate, caused a reduction in the observed [13C]bicarbonate signal, an increase in the [1-13C]lactate signal, a 
reduction in the [5-13C]glutamate signal, a nearly absent [1-13C]acetoacetate signal, and an increase in the [1-13C]
acetylcarnitine signal. All of these observations fit into a detailed narrative of substrate selection between pyru-
vate and butyrate in the myocardium (Fig. 5b).
The presence of medium or short chain fatty acids can severely restrict the entry of pyruvate into the TCA 
cycle as well as increase the lactate pool size in perfused hearts14. These results are largely duplicated in vivo, with 
the caveat that the pyruvate and butyrate co-injection did not take place over a period long enough to establish 
a metabolic steady state. High concentrations of pyruvate can partially overcome PDH inhibition by high fatty 
acid concentrations36. Hence, the production of [13C]bicarbonate was only halved as opposed to abolished when 
butyrate was also present, as observed in perfused rat heart22, and the lactate signal changed only marginally. 
Nevertheless these results indicate an almost instantaneous adaptation of myocardial metabolism to substrate 
availability.
These changes were also a direct reflection of butyrate uptake in the myocardium. The increase in [1-13C]
acetylcarnitine and the decrease of the [5-13C]glutamate and [1-13C]acetoacetate signals indicate competition 
from pyruvate for the limited number of free CoA units in the mitochondria (Fig. 5a). Acetylcarnitine serves as a 
buffer for extra acetyl units that exceed the capacity of the TCA cycle for oxidation and this circulation of acetyl 
groups is a fast, well equilibrated process37–39. When pyruvate was co-injected, free CoA was rapidly reacted to 
acetyl-CoA, and the extra acetyl units derived from butyrate oxidation were stored by reaction with carnitine, 
resulting in the increased observed acetylcarnitine. The lowering of the [5-13C]glutamate signal can be accounted 
for by the same competitive phenomena; [1-13C]pyruvate cannot produce labeling of glutamate in the myocar-
dium. However, identification of the mechanism(s) underlying the decreased glutamate signal upon co-injection 
will require further studies due to the considerations regarding glutamate-α -ketoglutarate exchange.
The mitochondrial pyruvate transporter preferentially antiports acetoacetate over any ion except hydrox-
ide40,41. Upon co-injection of pyruvate, we hypothesize that the consequent lack of free, unlabeled acetoacetate 
available for exchange short-circuits the process of pseudoketogenesis. Further experiments, for example block-
ing the mitochondrial pyruvate transporter, would be required to confirm this hypothesis, but this explanation 
seems straightforward given the previous work40.
In the case of fasting, co-injection resulted in a similar set of results to the fed control, but with some nota-
ble differences. Similar to the results with pyruvate only, fasting quenched the appearance of [13C]bicarbonate. 
Compared to the fed state, the sum of the products of hyperpolarized [1-13C]butyrate metabolism trended lower 
(Supplemental Fig. S3). But, the acetylcarnitine signal was the only driver of this difference. Fasting caused a sig-
nificant increase in the signal of acetoacetate. Given what is known about the increase in concentration of ketone 
bodies in fasting, the nominal increase in acetoacetate signal is most likely due to restored free acetoacetate avail-
ability and increased pseudoketogenesis (Fig. 5d). Further experiments varying the dose of pyruvate should serve 
to confirm this explanation. The near equivalence of the glutamate signal between the fed and fasted co-injection 
depends upon both TCA cycle turnover and Vx. Interpretation of the data would demand other independent 
measures of both pathways.
In summary, two separate agents, hyperpolarized [1-13C]pyruvate and hyperpolarized [1-13C]butyrate, were 
used as controls for a new protocol that measures substrate selection by the simultaneous injection of both agents. 
The substrate competition experiment has been shown capable of measuring carbohydrate versus fatty acid uti-
lization in the in vivo heart, as evidenced by statistically significant changes in the [13C]bicarbonate signal (evi-
dence of fatty acid competition with pyruvate) and in glutamate and acetoacetate signals (evidence of pyruvate 
displacement of fatty acids for the production of acetyl-CoA). These experiments demonstrate that the chemical 
selectivity inherent to magnetic resonance, when paired with the sensitivity enhancement of hyperpolarization, 
can be harnessed to produce a protocol that assesses substrate selection in real time, in vivo, in the functioning 
heart.
No changes were observed between fed and fasted states in vivo in a recent study using hyperpolarized [1-13C]
butyrate22 whereas many significant differences were detected in the present study. This can likely be attributed 
to increased spectral resolution at the higher magnetic field strength of 9.4 T used here. The clinical potential 
of the use of 13C hyperpolarized magnetic resonance techniques to probe in vivo metabolism has been recently 
discussed and the first trials in humans for application in cancer monitoring and diagnosis has already been com-
pleted42. Applications in cardiology also seem at least as promising, and are expected to affect both preclinical and 
clinical practice43. The protocol suggested here should augment the usefulness of hyperpolarized imaging further.
Biological significance. Pyruvate has been suggested as a treatment for heart failure, where its admin-
istration has been shown to increase contractility. Mechanistically, this increase in function was attributed to 
increased transport of Ca2+ ions44. However, as aforementioned, pyruvate produces more equivalents of ATP per 
mole of O2 consumed than any other substrate6. Due to the superior sensitivity and time resolution (1 s or even 
lower) available with hyperpolarized MR, it is possible to observe kinetic processes in vivo that were previously 
amenable to study only in cell culture models. If the mitochondrial pyruvate carrier indeed antiports acetoacetate 
and other competing substrates40,41, this would alter myocardial substrate selection for acetyl-CoA production. 
We propose that the beneficial effects of pyruvate administration are not only mediated by Ca2+ efflux but also by 
optimization of the myocardial efficiency as promoted by the export of substrates that compete with pyruvate for 
oxidation. This hypothesis is amenable to testing in the perfused heart and suggests concurrent treatment with 
pyruvate and PDH kinase inhibitors should maximally increase energy availability in the myocardium, perhaps 
as an acute treatment for myocardial infarction or failure.
www.nature.com/scientificreports/
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Study limitations. Hyperpolarization is limited by the 13C longitudinal relaxation time (T1) inherent to the 
molecules used for the studies45. While glucose would be a more obvious choice for this protocol, the additional 
enzymatic steps associated with glycolysis along with the short 13C T1 in all carbon positions of the glucose mol-
ecule greatly reduce the signal intensity of the metabolites relevant for the study of substrate competition. Our 
choice of [1-13C]pyruvate, which has a T1 at 9.4 T of ~45 s, implies that we are not measuring glycolytic metab-
olism, except indirectly through exchange with lactate. Lactate could also be used as a substitute for pyruvate, 
but the T1 of [1-13C]lactate is ~25 s in solution, considerably shorter than pyruvate. A similar rationale led us to 
choose butyrate as the surrogate for fatty acid oxidation. Butyrate is a short chain fatty acid that does not have 
to be solubilized with albumin, a known source of T1 relaxation21. Binding of a compound, including any long 
chain fatty acid tested, to albumin is sufficient to destroy the hyperpolarized signal (data not shown). Other water 
soluble fatty acids like [1-13C]octanoate could have been used46, but the increased number of unlabeled carbons 
subject to β -oxidation would have further halved the signals associated with fatty acid utilization without pro-
viding any information on the activity of fatty acid transporters like carnitine palmitoyl transferase I (CPT-I)13. 
The use of [1-13C]acetate would ensure a 100% transfer of labeled carbons, and the detection of the TCA cycle 
intermediate citrate, but it does not follow β -oxidation and the resonance of [1-13C]acetate overlaps with that 
of [5-13C]glutamate26,30. The lack of facilitated transport of butyrate as butyrylcarnitine by CPT-I is the primary 
drawback of butyrate as a molecular imaging agent, as CPT-I is a primary point of regulation for fatty acid oxida-
tion13. Despite its limitations, the use of the short chain fatty acid butyrate still provides unprecedented data about 
substrate competition and β -oxidation, as evidenced by the data presented here. Although CPT-I is bypassed and 
no information can be obtained related to the long chain fatty acid transport process itself, the insights gained are 
still expected to be diagnostic of myocardial dysfunction.
Some objections have been raised to the high concentrations of the exogenous agents used for these experi-
ments, with claims that bolus administration can produce flux through pathways due to thermodynamic effects. 
However, the short T1 of the hyperpolarized carbons works in the favor of the experiment. Before pool sizes can 
change noticeably from the challenge of the injected substrates, the experiment is over. From a safety perspec-
tive, high concentrations of injected pyruvate have been shown safe in the first human hyperpolarized imaging 
experiments42 with injected doses up to 0.10 mmol/kg. We have no reason to believe butyrate would not have a 
similar safety profile.
Conclusions
The combination of HP pyruvate and butyrate provides unprecedented insight into the selection of carbohy-
drates and fatty acids for oxidation in the myocardium in real-time, and enables a noninvasive and simultaneous 
measurement of different enzymatic pathways. The co-injections of hyperpolarized metabolic fuels was sensitive 
to a simple metabolic perturbation and is thus promising for mechanistic studies of myocardial energetics. The 
results shown here lead us to hypothesize that injection of a bolus of exogenous pyruvate might increase cardiac 
function not only due to Ca2+ modulation but also due to the export of substrates less efficient than pyruvate for 
ATP production.
Methods
Animals. All studies were performed between 10 am and 2 pm, and all animal experiments were conducted 
according to federal ethical guidelines. The study was approved by the EPFL Animal Care and Use Committee. 
Wild-type male Sprague Dawley rats (n = 36, 281 ± 26 g) were anesthetized with 1.5% isoflurane in oxygen. 
Catheters were placed into the femoral vein for substrate delivery and in the artery to monitor the blood pressure 
used for cardiac triggering, as previously described26,30,47. The respiration rate, cardiac rhythm, and temperature 
were monitored and maintained stable, and were not affected by the injections. Plasma glucose concentrations 
were quantified with the glucose oxidase method using two multi-assay analyzers (GW7 Micro-Stat, Analox 
Instruments, London, UK). Animals were exposed to an injection of hyperpolarized butyrate (n = 12), pyruvate 
(n = 10) or both (n = 14) and each group was divided to be in a fed or fasted state (Table 2). Six different groups 
were studied and each animal was injected once. The animals were fasted overnight.
Sample preparation and hyperpolarization protocol. Sodium [1-13C]butyrate and sodium [1-13C]
pyruvate (Sigma-Aldrich, Buchs, Switzerland), were hyperpolarized for 2.5 h in a 5 T custom-designed DNP 
polarizer48,49. Substrates were prepared separately using TEMPO nitroxyl radicals as previously described26,29, 
and were combined in the polarizer to yield identical concentrations of both 13C labeled pyruvate and butyrate. 
Using an automated process50 the sample was rapidly dissolved and transferred within 2 s following dissolution to 
a separator/infusion pump, containing 0.6 mL of phosphate buffered saline and heparin, located inside the bore 
of the MR scanner. Subsequently, 800 μ L of a 70 mM 13C-labeled hyperpolarized substrate solution was automat-
ically infused into the animal, yielding an average injected substrate dose of 0.19 mmol/kg. Typical polarization 
levels were 13 ± 2%.
In vivo magnetic resonance imaging and spectroscopy. Measurements were carried out in a horizon-
tal bore 9.4 T magnet (Magnex Scientific, Oxford, UK) with a Direct Drive spectrometer (Agilent, Palo Alto, CA, 
USA). A custom-made radiofrequency (RF) hybrid probe, consisting of a 10 mm diameter proton surface coil and 
a pair of 10 mm diameter 13C surface coils in quadrature mode, was positioned over the chest of the rat for trans-
mission and reception. A hollow glass sphere with a 3 mm inner diameter (Wilmad-LabGlass, NJ, USA) was filled 
with an aqueous 1 M [1-13C]glucose solution and used to adjust the radiofrequency (RF) excitation pulse power 
and set the reference frequency. Acquisition of gradient echo proton images confirmed the correct placement of 
the coil and was used to determine the voxel used for shimming.
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Cinematographic images (field of view = 40 × 40 mm2; matrix size: 256 × 256; repetition time TR = 140 ms; 
echo time TE = 4.5 ms; number of averages = 8; number of frames: 14; slice thickness: 1 mm) were acquired to 
confirm and set the timing of the cardiac trigger in the end-diastolic phase. The cardiac trigger was typically sent 
50 or 60 ms after the maximum observed blood pressure. Cardiac triggered and respiratory gated shimming was 
performed using the FAST(EST)MAP gradient shimming routine51 to reduce the localized proton line width in a 
myocardial voxel of 4 × 5 × 5 mm3 to 20–30 Hz acquired with stimulated echo localized spectroscopy (STEAM), 
resulting in a non-localized proton line width of 80–120 Hz. The MR console was triggered to start acquisition at 
the beginning of the automated injection process. Series of single pulse acquisitions were sequentially recorded 
using 30° adiabatic RF excitation pulses (BIR-4)52, with 1H decoupling using WALTZ53. Free induction decays 
were acquired with 4129 complex data points over a 20 kHz bandwidth. All acquisitions were cardiac triggered 
and respiratory gated, resulting in a nominal TR between 3 and 3.5 s. The adiabatic pulse offset and power were 
calibrated to ensure that the RF excitation angle θ = 30° for all observed metabolites in the entire tissue of interest, 
and was sufficient to excite the entire range of observable resonances from 100 to 220 ppm. Following in vivo data 
acquisition, a 200 μ L liquid sample was extracted from the separator/infusion pump to retrospectively determine 
the precise injected substrate concentrations.
Data analysis. The 13C MR spectra were summed and analyzed with Bayes (Washington University, St. Louis, 
MO, USA) as previously described and metabolite resonance areas were calculated26,47. All metabolite areas were 
normalized to their hyperpolarized injected precursor to determine specific metabolite ratios.
Statistical Methods. Statistics on the metabolite ratios were computed via two-way unbalanced ANOVA, 
considering the factors of “nutritional state” and “injected substrates”. In case the ANOVA analysis reported sig-
nificant interaction between the two factors, specific instances were further analyzed via two-tailed student t-tests 
for unpaired data with equal variance. All data were expressed as mean ± standard error of the mean (SEM).
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